Adaptive AAC for Communication Disorders
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to develop a communication device that adapts to each user’s physical abilities, enhancing communication for those with severe motor impairments. Participants will test both an experimental and a generic communication system (Adaptive AAC) to determine which is most effective for them. The trial targets individuals with conditions like cerebral palsy or spinal cord injuries who require alternative communication methods. Suitable participants should be able to spell, follow directions, and have some control over their head, hand, or foot. As an unphased trial, this study offers participants the chance to contribute to innovative solutions that could significantly improve communication for those with severe motor impairments.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this AAC system is safe for communication disorders?
Studies have shown that augmentative and alternative communication (AAC) systems are generally safe for users. Research indicates that similar AAC methods have not widely reported negative effects, suggesting that the new AAC under study should be well-tolerated.
For the standard AAC, safety is also well-documented. A review of AAC tools for children with autism did not report significant safety concerns. Overall, both the new and standard AAC systems appear to have good safety records based on existing evidence.12345Why are researchers excited about this trial?
Researchers are excited about the Adaptive AAC for Communication Disorders trial because it explores innovative communication interfaces designed to enhance how individuals with communication disorders express themselves. Unlike traditional AAC (Augmentative and Alternative Communication) systems, which may use static symbols or text-based methods, the experimental AAC in this trial adapts to the user's needs in a dynamic way, potentially offering more personalized and efficient communication options. This adaptability could lead to improved user engagement and more effective communication, which is a significant step forward from the generic AAC systems currently in use.
What evidence suggests that this trial's AAC systems could be effective for communication disorders?
Studies have shown that Augmentative and Alternative Communication (AAC) systems can greatly assist people with speech difficulties. Research indicates that 89% of AAC users experienced improved communication abilities. One study found that one-third to half of children with limited speech benefitted from AAC use. For general AAC systems, research focuses on enhancing their effectiveness for individuals with severe speech and language issues. In this trial, participants will use both Experimental and Generic AAC systems. Both types offer promising ways to improve communication, particularly for individuals with conditions such as autism, Alzheimer's, or Parkinson's disease.678910
Who Is on the Research Team?
Gianluca De Luca, M.S.
Principal Investigator
Altec Inc.
Are You a Good Fit for This Trial?
This trial is for individuals aged 6 or older with developmental communication disorders who can spell, follow instructions, and read large text. They must be able to attend multiple testing sessions and have voluntary muscle control in the head, hand, or foot without medical restrictions on movement.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive both Experimental and Generic AAC systems to communicate, focusing on usability, improved performance, acceptance, and perceived benefit
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Experimental AAC
- Generic AAC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Altec Inc.
Lead Sponsor
University of Nebraska
Collaborator